Aeterna Zentaris Stock Price

-0.0104 (-1.14%)


52 Week Range


Best deals to access real time data!
Big Cap Pro
Monthly Subscription
for only
Small Cap Pro
Monthly Subscription
for only
DDE w/Realtime (Monthly)
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
Aeterna Zentaris Inc AEZS NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
-0.0104 -1.14% 0.90 04:42:43
Open Price Low Price High Price Close Price Prev Close
Bid Price Ask Price Spread News
0.905 0.95 0.045 - -
Trades Volume Avg Volume 52 Week Range
7 1,775 6,851,343 0.29 - 3.62
Last Trade Time Type Quantity Stock Price Currency
04:45:24 20 $ 0.905 USD

Aeterna Zentaris Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 56.41M 62.68M 16.44M $ 543.03k $ - 0.25 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - 0.00% - -

more financials information »

Aeterna Zentaris News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical AEZS Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week1.091.110.900.96192023,518,449-0.19-17.43%
1 Month1.261.420.901.155,735,663-0.36-28.57%
3 Months0.7353.620.641.6720,010,0930.16522.45%
6 Months0.36833.620.291.4511,434,2710.5317144.37%
1 Year0.903.620.291.257,044,5110.000.0%
3 Years1.405.58690.291.322,536,816-0.50-35.71%
5 Years4.335.590.291.501,792,580-3.43-79.21%

Aeterna Zentaris Description

AEterna Zentaris Inc is a biopharmaceutical company commercializing & developing therapeutics & diagnostic tests. The company's product, Macrilen (macimorelin), is the oral test indicated for the diagnosis of adult growth hormone deficiency (GHD). Macrilen is marketed in the U.S. through a license agreement with Novo Nordisk & the company receives royalties on sales. Aeterna owns all rights to macimorelin outside of the U.S. & Canada. It is leveraging the clinical success & safety profile of macimorelin to develop it for the diagnosis of child-onset GHD. The company is actively pursuing opportunities to commercialize macimorelin in the EU & the rest of the world.

Your Recent History
Aeterna Ze..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.